External Quality Assurance for Heparin Monitoring

Abstract

Although there is considerable debate regarding the usefulness of laboratory heparin monitoring, these test processes reflect a substantial portion of hemostasis laboratory activity. Accordingly, external quality assurance (EQA) remains an essential component of such testing, and ensures that laboratories provide the best available service for patient management. This report provides an overview of recent and past EQA related to heparin monitoring using data from the Royal College of Pathologists of Australasia Haematology Quality Assurance Program, and heparin-containing plasma samples with concentrations ranging from 0 to 1.4 U/mL. Laboratory tests evaluated comprised activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen, and anti-Xa assays. Results for APTT and TT testing were largely as expected, showing prolongation with increasing concentrations of heparin. Fibrinogen assays were generally unaffected by the presence of therapeutic heparin levels. Although cross-laboratory median values for the anti-Xa assay were close to target values, substantial interlaboratory variation in results, expressed as coefficient of variation (CV), was observed in all exercises conducted over an 8-year period (5 to 28% for low-molecular weight heparin [LMWH] and 19 to 37% for unfractionated heparin). Duplicate samples sent in consecutive surveys resulted in similar median values. The use of a survey-provided standard as assay calibrant improved CVs in earlier surveys, but not in the most recent survey.

Keywords

activated partial thromboplastin time - anti-Xa assay - low-molecular weight heparin - unfractionated heparin - external quality assurance

• References

• 1 Garcia DA, Baglin TP, Weitz JI, Samama MM ; American College of Chest Physicians. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl. 02) e24S-e43S
• 2 Kitchen S. Problems in laboratory monitoring of heparin dosage. Br J Haematol 2000; 111 (2) 397-406
• 3 Guervil DJ, Rosenberg AF, Winterstein AG, Harris NS, Johns TE, Zumberg MS. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Ann Pharmacother 2011; 45 (7–8) 861-868
• 4 Cuker A, Raby A, Moffat KA, Flynn G, Crowther MA. Interlaboratory variation in heparin monitoring: lessons from the Quality Management Program of Ontario coagulation surveys. Thromb Haemost 2010; 104 (4) 837-844
• 5 Cuker A. Unfractionated heparin for the treatment of venous thromboembolism: best practices and areas of uncertainty. Semin Thromb Hemost 2012; 38 (6) 593-599
• 6 Olson JD, Arkin CF, Brandt JT , et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998; 122 (9) 782-798
• 7 Favaloro EJ, Lippi G, Koutts J. Laboratory testing of anticoagulants: the present and the future. Pathology 2011; 43 (7) 682-692
• 8 Bounameaux H, de Moerloose P. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No. J Thromb Haemost 2004; 2 (4) 551-554
• 9 Greaves M ; Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost 2002; 87 (1) 163-164
• 10 Mackinlay N, Favaloro EJ, Arthur C, Smith J, Aboud M. A survey of heparin monitoring in Australasia. Pathology 1996; 28 (4) 343-347
• 11 Kitchen S, Iampietro R, Woolley AM, Preston FE. Anti-Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. Thromb Haemost 1999; 82 (4) 1289-1293
• 12 Kovacs MJ, Keeney M, MacKinnon K, Boyle E. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Clin Lab Haematol 1999; 21 (1) 55-60
• 13 Depasse F, Gilbert M, Goret V, Rolland N, Samama MM. Anti-Xa monitoring: inter-assay variability. Thromb Haemost 2000; 84 (6) 1122-1123
• 14 Rosenberg AF, Zumberg M, Taylor L, LeClaire A, Harris N. The use of anti-Xa assay to monitor intravenous unfractionated heparin therapy. J Pharm Pract 2010; 23 (3) 210-216
• 15 Bonar RA, Favaloro EJ, Adcock DM. Quality in coagulation and haemostasis testing. Biochem Med 2010; 20: 184-199
• 16 Favaloro EJ, Bonar R, Sioufi J , et al; Royal College Pathologists of Australasia Quality Assurance Program in Haematology. An international survey of current practice in the laboratory assessment of anticoagulant therapy with heparin. Pathology 2005; 37 (3) 234-238
• 17 Favaloro EJ, Bonar R, Aboud M , et al; RCPA QAP in Haematology. How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective. Lab Hematol 2005; 11 (3) 157-162
• 18 Cuker A, Ptashkin B, Konkle BA , et al. Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time. J Thromb Haemost 2009; 7 (1) 80-86
• 19 Ignjatovic V, Summerhayes R, Gan A , et al. Monitoring unfractionated heparin (UFH) therapy: which anti-factor Xa assay is appropriate?. Thromb Res 2007; 120 (3) 347-351
• 20 Favaloro EJ, Lippi G. Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against?. Clin Chem Lab Med 2011; 49 (5) 755-757